

**Curriculum Vitae**  
**Daniel James Rader, M.D.**  
**April 4, 2007**



**Office Address:** University of Pennsylvania Medical Center  
654 BRBII/III  
421 Curie Blvd.  
Philadelphia, PA 19104-6160  
Tel: 215/573-4176  
Fax: 215/573-8606  
E-mail address: rader@mail.med.upenn.edu

**Education:**

|      |      |  |
|------|------|--|
| 1981 | B.A. | Lehigh University, ( <i>summa cum laude</i> )              |
| 1984 | M.D. | Medical College of Pennsylvania ( <i>summa cum laude</i> ) |

**Postgraduate Training and Fellowship Appointments:**

|           |  |
|-----------|--|
| 1984-1985 | Internship, Internal Medicine, Yale-New Haven Hospital, New Haven, CT  |
| 1985-1987 | Residency, Internal Medicine, Yale-New Haven Hospital, New Haven, CT   |
| 1987-1988 | Chief Resident, Internal Medicine, Yale School of Medicine, New Haven, CT  |
| 1988-1991 | Medical Staff Fellow, Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland |

**Academic Appointments:**

|                    |  |
|--------------------|--|
| July 1991-Dec 1993 | Staff Scientist, Molecular Disease Branch, NHLBI, NIH  |
| Jan 1994-June 2000 | Assistant Professor of Medicine, University of Pennsylvania School of Medicine   |
| Jan 1994-June 2000 | Assistant Professor of Pathology and Laboratory Medicine (secondary appt), University of Pennsylvania School of Medicine           |
| July 2000-present  | Associate Professor of Medicine, Pathology and Laboratory Medicine, and Pharmacology University of Pennsylvania School of Medicine |
| July 2006-present  | Cooper-McClure Professor of Medicine   |

**Hospital and Administrative Appointments:**

|              |   |
|--------------|---|
| 1994-present | Director, Preventive Cardiovascular Medicine and Lipid Clinic<br>University of Pennsylvania Health System |
| 1996-present | Associate Program Director, General Clinical Research Center<br>University of Pennsylvania Medical Center |
| 1996-1998    | Institutional Review Board  |
| 1998-present | GCRC Advisory Committee, Children's Hospital of Philadelphia  |
| 2002         | Chair, Experimental Therapeutics Theme Group, Strategic Planning Initiative                               |
| 2002-present | Faculty Advisory Committee, Office of Human Research, Univ. Penn  |
| 2003-present | Chair, Scientific Advisory Committee, Molecular Diagnostics Genotyping Core                               |
| 2005-present | Program Director, General Clinical Research Center  |

University of Pennsylvania Medical Center

**Awards, Honors and Memberships in Honorary Societies:**

|           |   |
|-----------|---|
| 1979      | Phi Beta Kappa  |
| 1983      | Alpha Omega Alpha   |
| 1984      | Dean's Award, Medical College of Pennsylvania   |
| 1995      | WW Smith Charitable Trust Awardee   |
| 1996      | Outstanding Faculty Award, Department of Medicine   |
| 1997      | Donald B. Martin Outstanding Teacher Award  |
| 1999      | Election to American Society of Clinical Investigation  |
| 2000      | Established Investigator, American Heart Association  |
| 2000      | Burroughs Wellcome Fund Clinical Scientist Award in Translational Research  |
| 2002-2005 | Listing in "Top Doctors of Philadelphia" (Philadelphia Magazine)  |
| 2002      | Doris Duke Charitable Foundation Distinguished Clinical Investigator Award  |
| 2005      | Jeffrey M. Hoeg Award for Basic Science and Clinical Research, Arteriosclerosis, Thrombosis, and Vascular Biology Council of the American Heart Association |
| 2005      | 8 <sup>th</sup> Annual Gill Heart Institute Award for Outstanding Contributions to Cardiovascular Research  |
| 2005      | William Osler Patient Oriented Research Award, University of Pennsylvania School of Medicine  |
| 2005      | Cooper McClure Chair Professorship, University of Pennsylvania School of Medicine   |
| 2005      | Bristol Myers Squibb "Freedom to Discover" Unrestricted Cardiovascular Research Grant   |

**Memberships in Professional and Scientific Societies:**

National Societies:

American Federation for Medical Research  
American Association for the Advancement of Science  
American College of Physicians  
Arteriosclerosis, Thrombosis, and Vascular Biology Council of the American Heart Association  
American Society for Clinical Investigation

Local Societies:

American Heart Association, Southeastern Pennsylvania Affiliate (member, Board of Directors)

National Scientific Committees and Peer Review:

National American Heart Association Lipoproteins and Lipid Metabolism Research Study Committee, Member, 1990-1994  
American Heart Association Southeastern Pennsylvania Affiliate Grant Review Committee, Reviewer, 1995-1997  
Program Projects, NHLBI, NIH, Ad hoc reviewer, 1996  
Program Projects, NHLBI, NIH, Ad hoc reviewer, 1997  
General Clinical Research Center, San Francisco General Hospital, Site Visitor, 1997  
American Heart Association Mid-Atlantic Research Affiliate Grant Review Committee, Reviewer, 1998  
Program Projects, NHLBI, NIH, Ad hoc reviewer, 1998  
VA Merit Review Program, Ad hoc reviewer, 1998  
General Clinical Research Center, Rockefeller University Hospital, Site Visitor, 1998  
Cardiovascular Measurement Advisory Panel, National Committee for Quality Assurance, Member, 1998-present  
American Heart Association Mid-Atlantic Research Affiliate Grant Review Committee, Co-Chair, 1999  
VA Merit Review Program, Ad hoc reviewer, 1999  
Clinical Nutrition Research Units, NIDDK, NIH, Ad hoc reviewer, 1999  
Group Grant Application, Department of Biochemistry, University of Alberta, Canada, Site Visitor, 1999  
American Heart Association Mid-Atlantic Research Affiliate Grant Review Committee, Reviewer, 2000

Executive Committee, Arteriosclerosis Thrombosis and Vascular Biology Council, American Heart Association, 1999-2002  
 Program Chair, Arteriosclerosis Thrombosis and Vascular Biology Council, American Heart Association Scientific Sessions, November, 2001  
 Program Projects, NHLBI, NIH, Ad hoc reviewer, 2002  
 Vice-Chair, Gordon Conference on Lipid and Lipoprotein Metabolism, Meriden, New Hampshire, June, 2002  
 Program Co-chair, AHA ATVB meeting, May 8-10, 2003  
 Chair, Gordon Conference on Lipid and Lipoprotein Metabolism, Meriden, New Hampshire, June, 2004  
 Chair, Research Committee, American Heart Association Pennsylvania-Delaware Affiliate

#### **Editorial and Peer Review Activity:**

1999-present Editorial Board, Trends in Molecular Medicine  
 2000-present Editorial Board, Arteriosclerosis, Thrombosis, and Vascular Biology  
 2001-present Editorial Board, American Journal of Physiology (Endocrinology and Metabolism)  
 2002-present Editorial Board, Circulation  
 2002-present Editorial Board, Circulation Research  
 2005-present Editorial Board, Journal of Lipid Research

Reviewer, American Journal of Cardiology  
 Reviewer, Arteriosclerosis, Thrombosis, and Vascular Biology  
 Reviewer, Atherosclerosis  
 Reviewer, Biochemica Biophysica Acta--Lipid Metabolism  
 Reviewer, Cell Metabolism  
 Reviewer, Circulation  
 Reviewer, Circulation Research  
 Reviewer, Clinical Chemistry  
 Reviewer, Diabetes  
 Reviewer, Diabetes Care  
 Reviewer, Journal of Clinical Investigation  
 Reviewer, Journal of Lipid Research  
 Reviewer, Metabolism  
 Reviewer, Molecular and Cell Biology  
 Reviewer, Nature  
 Reviewer, Nature Medicine  
 Reviewer, New England Journal of Medicine  
 Reviewer, Proceedings of the National Academy of Sciences  
 Reviewer, Science

#### **Teaching and Education**

1. Outpatient Attending, Preventive Cardiovascular Medicine and Lipid Clinic
2. Lecturer, Curriculum 2000, Cardiovascular Block, University of Pennsylvania School of Medicine; 4 lectures per year; 1996-present.
3. Unit Coordinator, Molecular Basis of Gene Therapy, CAMB 610; 2 months per year; 1997-present.
4. Lecturer, Introduction to Patient Oriented Research Course, 1999-present

#### **Active NIH and Foundation Grant Support (not including industry-sponsored research)**

| Grant/sponsor  | Dates          |
|--|----------------|
| 3R01-HL55323 (D. Rader, PI)<br>NIH, NHLBI<br>"HDL metabolism: Influence of extracellular phospholipases" | 4/1/96-3/31/09 |
| 1R01-DK59533 (D. Rader, PI)  | 9/1/00-8/31/05 |

NIH, NIDDK

“Mechanisms of PI-related dyslipidemia and atherosclerosis”

P50-HL70128 (G. FitzGerald, PI)

5/1/02-4/30/07

NIH, NHLBI (SCOR in Atherosclerosis)

“Oxidative Modifications in Atherogenesis”

Project 4 (D. Rader, P.I.) “Antioxidant and Anti-inflammatory Mechanisms of HDL”

P01-HL22633 (M. Phillips, PI)

7/1/03-6/30/08

NIH, NHLBI

“Cellular and Molecular Biology of Lipoprotein Metabolism”

Project 3 (D. Rader, PI): “ApoA-I and reverse cholesterol transport *in vivo*”

PO1-HL62250 (G. FitzGerald, PI)

4/1/04-3/31/09

NIH/NHLBI

“Signal Transduction in Atherosclerosis”

Project 3 (D. Rader, PI) – “ApoE and Regulation of COX-2 in VSMCs”

1P01-HL59407 (J. Wilson, PI)

7/1/04-6/30/09

NIH, NHLBI

“DNA Viruses as Vectors for NHLBI Diseases”

Project 3 (D. Rader, PI): “Gene Therapy of Atherosclerosis”

P50 SCCOR (FitzGerald, PI)

05/1/06-04/30/11

NIH/NHLBI

“Lipids as modulators of the response to vascular injury”

Project 2 (D. Rader, PI): “The nicotinic acid receptor HM74A in vascular injury”

U01 (H. Feldman, PI)

9/29/01-9/28/08

NIH, NIDDK

“Prospective Cohort Study of Chronic Renal Insufficiency”

Role in Project: Director, Central Biochemistry Laboratory

M01-RR00040 (A. Rubinstein, P.I.)

12/1/02-11/30/07

General Clinical Research Center

NIH, NCRR

Role in Project: Program Director

K12-RR17625-01 (D. Rader, P.I.)

10/02-9/07

Mentored Career Development in Patient Oriented Research

NIH, NCRR

Role in Project: PI/Program Director

Clinical-Scientist Award in Translational Research

7/1/00-6/30/05

Burroughs Wellcome Fund

“Novel therapeutic approaches to atherosclerosis through modulation of HDL metabolism”

Role in Project: Principal Investigator

Doris Duke Distinguished Clinical Investigator Award

1/1/03-12/31/08

Doris Duke Charitable Foundation

“Genetics of Lipid Metabolism and Atherosclerosis”

Role in Project: Principal Investigator

**Lectures by Invitation** (Selected, since Jan 2000 only)

- January 13, 2000 "HDL prevention and treatment of coronary disease," Cardiology Grand Rounds, Robert Wood Johnson Medical School, New Brunswick, NJ.
- January 14, 2000 "HDL as a therapeutic target for atherosclerosis," Cardiology Grand Rounds, Yale University, New Haven, Connecticut.
- February 2, 2000 "Cardiovascular Risk Assessment" and "Lipid-lowering drug therapy," American College of Cardiology Conference at Snowshoe, Snowshoe, WV.
- March 11, 2000 "Oxidant stress and atherosclerosis," Symposium at American College of Cardiology Annual Meeting, Anaheim, CA
- April 1, 2000 "Gene therapy for atherosclerosis," Cardiovascular Symposium, Vascular Biology Meeting, Osaka, Japan
- April 26, 2000 "Gene therapy for atherosclerosis," International Symposium on Gene Therapy, Amsterdam, Netherlands
- June 25, 2000 "Liver-directed gene therapy beyond FH," International MEDPED Meeting, Stockholm, Sweden.
- July 30, 2000 "Role of endothelial lipase in HDL metabolism," Gordon Conference on Lipoproteins, Kimball Union Academy, NH.
- August 21, 2000 "Lipases and HDL," Kern Aspen Lipid Conference, Aspen, CO
- September 27, 2000 "HDL Metabolism and Atherosclerosis," St. Louis Lipid Club, St. Louis, MO
- October 2, 2000 "HDL as a target for Therapy," Endocrine Society Annual Meeting, Philadelphia, PA
- October 11, 2000 "HDL Metabolism and Atherosclerosis," Los Angeles Lipid Club, Los Angeles, CA
- October 12, 2000 "Regulation of HDL Metabolism," Cardiology Research Seminar, UCLA, Los Angeles, CA
- November 11, 2000 "Atherosclerosis Imaging," Sunday AM Program, American Heart Association Scientific Sessions, New Orleans, LA
- November 13, 2000 "HDL as a target for Therapy," Cardiovascular Seminar, American Heart Association Scientific Sessions, New Orleans, LA
- November 13, 2000 "Lipases and HDL," Cardiovascular Seminar, American Heart Association Scientific Sessions, New Orleans, LA
- January 16, 2001 "HDL Metabolism" Temple Univ Endocrinology Rounds, Philadelphia, PA
- March 17, 2001 "Lipids and Atherosclerosis: Breaking New Ground", University of Michigan Medical School presentation, Orlando, FL
- March 18, 2001 "Treating the dyslipidemic diabetic patient", American College of Cardiology 50<sup>th</sup> Annual Scientific Session, Orlando, FL
- March 22, 2001 "New approaches to assessing cardiac risks" and "HDL metabolism: A target for therapy for atherosclerosis", Kynett Memorial Foundation Seminar, Philadelphia, PA
- April 6, 2001 "HDL – New insights in HDL metabolism and reverse cholesterol transport" 3<sup>rd</sup> Nordic Meeting on Lipid Lowering, Copenhagen, Denmark
- April 19, 2001 "Peripheral markers of plaque formation in coronary risk", MCP Hahnemann University, Philadelphia, PA
- April 27, 2001 "The role of genetics in preventive cardiology", 5<sup>th</sup> Annual Symposium on Prevention of Coronary Disease, Miami, FL
- May 5, 2001 "HDL metabolism and atherosclerosis", 4<sup>th</sup> International Meeting on Platelets and Vascular Occlusion, Capri, Italy
- May 18, 2001 "Gene therapy in familial hypercholesterolemia: do we have to wait long?", Anacapri Workshop, Anacapri, Italy
- May 21, 2001 "Oxidative stress: A therapeutic target in atherosclerosis", 72<sup>nd</sup> Annual EAS Congress, Glasgow, UK
- June 23, 2001 "Mechanism of action and review of clinical trials for a novel cholesterol absorption inhibitor", Symposium, American Diabetes Association Annual Meeting, Philadelphia, PA
- June 23, 2001 "How to treat patients with low HDL – New insights from current research", American Diabetes Association Annual Meeting 61<sup>st</sup> Scientific Sessions, Philadelphia, PA
- August 11, 2001 "Molecular factors regulating HDL Metabolism", 2001 Robert Turner Memorial Conference, Southampton, Bermuda

- September 10, 2001 "HDL as a therapeutic target", DALM International Symposium, Giovanni Lorenzini Medical Foundation, New York
- September 10, 2001 "Raising low HDL-C: Treatment Strategies", DALM International Symposium, New York
- September 11, 2001 "Can we achieve new standard for risk reduction in the prevention and treatment of CAD?", DALM International Symposium, New York
- November 2, 2001 "New advances in management of lipid disorders", Temple University, Philadelphia, PA
- November 10, 2001 "Recent insights into vascular protection by HDL", AHA Symposium, Merck, Anaheim, CA
- November 10, 2001 "Can we achieve new standard for risk reduction in the prevention and treatment of CAD?", Symposium, American Heart Association, Anaheim, CA
- November 10, 2001 "Clinical considerations in the management of patients with the metabolic syndrome", Metabolic Syndrome and Cardiovascular Disease Symposium, AHA Symposium, Anaheim, CA
- November 10, 2001 "Future Outlook: Changing perspectives on best practice", Reinventing Treatment of Dyslipidemia, AHA symposium, Anaheim, CA
- November 27, 2001 "Genetic control of lipids and atherosclerosis", MCP Hahnemann Medical Seminar, MCP Hahnemann University, Philadelphia, PA
- November 28, 2001 "HDL as a target for therapy", MCP Hahnemann Medical Seminar, MCP Hahnemann University, Philadelphia, PA
- February 26, 2002 "HDL remodeling: Target for therapeutic intervention?", HDL Cholesterol Conference, The Knowledge Foundation - Boston, MA
- March 16, 2002 "Novel approaches to inflammation and their impact on cardiovascular outcomes", Mediators of Inflammation Symposium – ACC, Atlanta, GA
- May 22, 2002 "Regulation of HDL metabolism", Vascular Biology Working Group - London Ontario
- June 5, 2002 "Gene transfer for lipid disorders and atherosclerosis", American Society of Gene Therapy - Boston, Mass
- June 17, 2002 "Lipases in HDL metabolism and reverse cholesterol transport", Gordon Research Conference – Meridian, NH
- July 29, 2002 "Genomics of lipid abnormalities/cardiovascular disease", AACTG Meeting – Arlington, VA
- September 28, 2002 "Interrelationships between metabolic syndrome, inflammation, and HDL metabolism", Interdisciplinary Council Meeting on Coronary Heart Disease – New York, NY
- October 4, 2002 "HDL as a target for new therapies for atherosclerosis", Cleveland Clinic – Cleveland, OH
- October 5, 2002 "New approaches to targeting HDL metabolism in treating atherosclerosis", Southeast Lipid Research Conference – Atlanta, GA
- October 25, 2002 "Vascular protection & HDL: new aspects", Interdisciplinary Cardiovascular Symposium – Barcelona, Spain
- November 3, 2002 "HDL and regression of atherosclerosis", American Society of Nephrology – Philadelphia, PA
- November 16, 2002 "HDL as therapeutic target: progress and controversies", AHA Symposium: What's new in diabetes, atherothrombosis, protective effects of HDL, obesity, and hypertension – Chicago, IL
- November 18, 2002 "The role of the LDL receptor in apoB secretion", CV session, AHA Scientific Sessions – Chicago, IL
- December 4, 2002 "Recent advances in targeting lipids in the prevention of atherosclerotic vascular disease", Albert Einstein Medical Center – Philadelphia, PA
- January 24, 2003 "Endothelial lipase: Role of a new lipase acting on lipoproteins", Cleveland Clinic – Cleveland, OH
- March 29, 2003 "Mechanisms of atherothrombosis and clinical implications", ACC Symposium - Chicago, IL
- March 29, 2003 "The high risk associated with patients with diabetes or the metabolic syndrome", ACC Symposium – Chicago, IL

|                    |   |
|--------------------|---|
| March 29, 2003     | "Lp-PLA <sub>2</sub> : Metabolic properties and relationship to atherosclerosis", ACC Symposium – Chicago, IL   |
| May 21, 2003       | "HDL as a therapeutic target for atherosclerosis", Cardiology Grand Rounds, UCLA – Los Angeles, CA  |
| May 27, 2003       | "HDL as a therapeutic target for atherosclerosis", Cardiology Grand Rounds, Hartford Hospital – Hartford, CT  |
| May 30, 2003       | "Endothelial lipase: a key modulator of HDL metabolism", University of Alabama – Birmingham, AL   |
| June 16, 2003      | "Lipases and regulation of HDL metabolism," Gordon Conference on Atherosclerosis, Meriden, NH   |
| June 21, 2003      | "HDL as a therapeutic target for atherosclerosis", Cardiology Grand Rounds, Yale-New Haven Hospital, – New Haven, CT  |
| July 12, 2003      | "Update Endothelial lipase", International Symposium on Triglycerides – New York  |
| July 24, 2003      | "Lipoproteins – from basic research to clinical application", American Society for Clinical Laboratory Science – Philadelphia, PA                             |
| September 20, 2003 | "Oxidation and atherosclerosis, lessons from animal models", National Atherosclerosis Forum – Halifax, Nova Scotia  |
| October 9, 2003    | "Pathophysiology of HDL disorders", Johns Hopkins University – Baltimore, MD  |
| October 20, 2003   | "HDL as a Therapeutic Target for Atherosclerosis", Cardiovascular Drug Discovery Symposium – Philadelphia, PA   |
| November 9, 2003   | "Emerging Risk Factors", AHA Symposium - Orlando, FL  |
| November 9, 2003   | "Hereditary dyslipidemias", AHA Cardiovascular Seminar, AHA Symposium – Orlando, FL   |
| November 9, 2003   | "Assessing cardiovascular risk: Beyond traditional risk factors", AHA Symposium – Orlando, FL   |
| November 10, 2003  | "Reverse cholesterol in humans", AHA Cardiovascular Seminar, AHA Symposium – Orlando, FL  |
| December 19, 2003  | "LDL-Cholesterol: A new light with ezetimibe – HDL-Cholesterol: A precious but difficult therapeutic target", ACC Symposium – New York                        |
| May 12, 2004       | "From rare genetic disorders to treatments for common conditions: Translational research in lipids and atherosclerosis", Boston University – Boston, MA       |
| June 9, 2004       | "Update on HDL", Albert Einstein Medical Center – Philadelphia, PA  |
| June 11, 2004      | "From rare genetic disorders to treatments for common conditions: Translational research in lipids and atherosclerosis", Temple University – Philadelphia, PA |
| June 30, 2004      | "Update on lipids lowering", Paoli Memorial Hospital – Paoli, PA  |
| September 10, 2004 | "Lipoproteins and other related risk factors", CV Biomarkers Symposium – Bethesda, MD   |
| September 15, 2004 | "New developments in assessing and reducing cardiovascular risk", Holy Redeemer Hospital – Meadowbrook, PA  |
| October 4, 2004    | "Recent and future advances in lipid management", Graduate Hospital – Philadelphia, PA  |
| October 15, 2004   | "The Biology of Endothelial Lipase" – HDL Summit, Versailles, France  |
| November 6, 2004   | "Diabetic Dyslipidemia" – AHA Symposium, New Orleans, LA  |
| November 7, 2004   | "CETP inhibition and HDL cholesterol" – AHA Symposium, New Orleans, LA  |
| November 7, 2004   | "Emerging issues and therapeutic options in diabetic dyslipidemia" – AHA Symposium, New Orleans, LA   |
| November 8, 2004   | "The clinical promise of Lp-PLA <sub>2</sub> : A new marker, therapeutic target or both?" - AHA Symposium, New Orleans, LA                                    |
| November 9, 2004   | "The promise of pharmacogenomics" - AHA Plenary Session, New Orleans, LA  |
| December 12, 2004  | "HDL cholesterol "on the rise": CETP inhibitors and other evolving approaches" – ACC Symposium, New York, NY  |
| January 4, 2005    | "Update on management of lipids" – Pennsylvania Hospital, Philadelphia, PA  |
| January 12, 2005   | "HDL as a therapeutic target" – Philadelphia Endocrine Society, Philadelphia, PA  |
| January 29, 2005   | "Focus on HDL: Basic and clinical developments" – NELA Meeting, New York, NY  |
| February 3, 2005   | "HDL as a therapeutic target for atherosclerosis" – Medical Grand Rounds, Washington University, St. Louis, MO  |

|                    |   |
|--------------------|---|
| March 4, 2005      | "Molecular regulation of reverse cholesterol transport" – Deuel Conference on Lipids, Dana Point, CA  |
| March 23, 2005     | "Molecular regulation of HDL metabolism and therapeutic implications" – Research Symposium Keynote Address, Lankenau Hospital, Wynnewood, PA  |
| April 7, 2005      | "Advances in modulating lipid metabolism in the prevention and regression of atherosclerosis" – Himmelfarb Lectureship, Sinai Hospital of Baltimore, Baltimore, MD                            |
| April 14, 2005     | "Molecular regulation of reverse cholesterol transport" – Keystone Symposium, Whistler, BC  |
| April 20, 2005     | "HDL as a therapeutic target" – Cardiology Grand Rounds, Johns Hopkins Hospital, Baltimore, MD  |
| May 13, 2005       | "HDL metabolism as a therapeutic target for atherosclerosis" – Endocrine Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA   |
| June 21, 2005      | "Molecular regulation of HDL metabolism and reverse cholesterol ester transport in vivo" – Gordon Research Conference on Atherosclerosis, Meriden, NH   |
| July 14, 2005      | "Update on endothelial lipase" – 2 <sup>nd</sup> International Symposium on Triglycerides and HDL" – New York, NY   |
| October 7, 2005    | "HDL as a therapeutic strategy" – Gill Heart CV Research Day – Lexington, KY  |
| October 29, 2005   | "HDL Cholesterol update: CETP inhibitors and other evolving approaches" – Morristown Memorial Hospital VC Symposium – Morristown, NJ  |
| November 2, 2005   | "Advances in the prevention of coronary disease"--Jefferson Kynett CV Conference – Thomas Jefferson University – Philadelphia, PA   |
| November 5, 2005   | "Targeting HDL as a component of cardiovascular risk reduction" – Affairs of the Heart Symposium – Newark, DE   |
| December 11, 2005  | "HDL Cholesterol update: CETP inhibitors and other evolving approaches" – ACC Cardiovascular Symposium – NYC  |
| January 4, 2006    | "From rare genetic conditions to novel therapeutics for common disorders" – Rockefeller University Hospital – NYC   |
| March 30, 2006     | "HDL as a therapeutic target for atherosclerosis" – New York University Medical School – NYC  |
| April 4, 2006      | "Molecular regulation of reverse cholesterol transport" – Keystone Symposium – Keystone, CO   |
| June 10, 2006      | "Pathways regulating HDL levels" – American Diabetes Association Conference – Washington, DC  |
| June 16, 2006      | "From rare genetic conditions to treatments for common disorders: translational cardiovascular medicine in practice" – Thomas Jefferson University Translational Symposium – Philadelphia, PA |
| June 16, 2006      | "Update on HDL as a therapeutic target" – Temple University Lecture Series – Philadelphia, PA   |
| July 5, 2006       | "Molecular physiology of HDL metabolism and reverse cholesterol transport" – Gordon Conference on Lipoprotein Metabolism – Mt Holyoke, MA   |
| September 25, 2006 | "Dysregulation of HDL metabolism and reverse cholesterol transport in the metabolic syndrome" – Metabolic Syndrome Symposium – Boston, MA   |
| November 4, 2006   | "Update on management of lipids" – Affairs of the Heart Symposium – Newark, DE  |
| November 11, 2006  | "LXR/FXR Agonists" – National Lipid Association Masters Summit Conference – AHA Scientific Sessions – Chicago, IL   |
| November 12, 2006  | "HDL as a target for decreasing cardiovascular risk: Novel approaches for treating mixed dyslipidemia" – AHA Scientific Sessions – Chicago, IL  |
| November 13, 2006  | "Complimentary roles of SR-B1 and ABCA1 reverse cholesterol transport" – AHA Scientific Sessions – Chicago, IL  |
| January 18, 2007   | "Preventative Cardiology Metabolic Syndrome" – Cooper University Hospital – Camden, NJ  |
| January 26, 2007   | "Current and future approaches to lipid disorders: 2007" – Temple University Hospital – Philadelphia, PA  |
| March 26, 2007     | "Targeting HDL to prevent coronary disease: Where do we go from here?" – ACC Scientific Sessions – New Orleans, LA  |



## Bibliography

### Peer Reviewed Original Publications and Reviews

1. Sparks CE, Rader DJ, Marsh JB. Metabolism of two forms of apolipoprotein B of VLDL by rat liver. *J Lipid Res* 24:156-166; 1983.
2. Lohse P, Kindt MR, Rader DJ, Brewer HB Jr. Genetic polymorphism of human plasma apolipoprotein A-IV is due to nucleotide substitutions in the apolipoprotein A-IV gene. *J Biol Chem* 265:10061-10064; 1990.
3. Lohse P, Kindt MR, Rader DJ, Brewer HB Jr. Human plasma apolipoproteins A-IV-0 and A-IV-3: Molecular basis for two rare variants of apolipoprotein A-IV-1. *J Biol Chem* 265:12734-12739; 1990.
4. Charnas LR, Bernardini I, Rader DJ, Hoeg JM, Gahl WA. Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. *N Engl J Med* 324:1318-1325; 1991.
5. Lohse P, Kindt MR, Rader DJ, Brewer HB Jr. Three genetic variants of human plasma apolipoprotein A-IV. *J Biol Chem* 266:13513-13518; 1991.
6. Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer HB Jr. Metabolism of apolipoprotein A-I in high density lipoprotein particles LpA-I and LpA-I,A-II. *J Lipid Res* 32:1849-1959; 1991.
7. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples. *Blood* 78:387-393; 1991.
8. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein, ApoA-I<sub>Iowa</sub>, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. *J Lipid Res* 33:755-763; 1992.
9. Lohse P, Rader DJ, Brewer HB Jr. Heterozygosity for apolipoprotein E-4<sup>Philadelphia</sup> (Glu<sub>13</sub>->Lys,Arg<sub>145</sub>->Cys) is associated with incomplete dominance of Type III hyperlipoproteinemia. *J Biol Chem* 267:13642-13646; 1992.
10. Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE, Brewer HB Jr. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. *Arteriosclerosis and Thrombosis* 12:843-848; 1992.
11. Mautner SL, Sanchez JA, Rader DJ, Mautner GC, Ferrans VJ, Fredrickson DS, Brewer HB Jr, Roberts WC. The heart in Tangier disease: Severe coronary atherosclerosis with near absence of high-density lipoprotein cholesterol. *A J Clin Path* 98:191-198; 1992.
12. Reblin T, Rader DJ, Beisiegel U, Greten H, Brewer HB Jr. Correlation of apolipoprotein(a) Isoforms with Lp(a) density and distribution in fasting plasma. *Atherosclerosis* 94:223-232; 1992.
13. Shibusawa Y, Ito Y, Ikewaki K, Rader DJ, Brewer HB Jr. Counter-current chromatography of lipoproteins with a polymer phase system using the cross-axis synchronous coil planet centrifuge. *J Chromatography* 596:118-122; 1992.
14. Schaefer JR, Rader DJ, Brewer HB Jr. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. *Current Opinion in Lipidology* 3:227-232; 1992.
15. Rader DJ and Brewer HB Jr. Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein. *JAMA* 267:1109-1112; 1992.
16. Weiss JS, Rodrigues M, Kruth HS, Rajagopalan S, Rader DJ, Kachadoorian H. Panstromal Schnyder's Corneal Dystrophy. Ultrastructural and histochemical studies. *Ophthalmology* 99:1072-1081; 1992.
17. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. *Science* 258:999-1001; 1992.
18. Benvenga S, Cahnmann HJ, Rader DJ, Kindt M, Robbins J. Thyroxine binding to the apolipoproteins of high density lipoproteins HDL<sub>2</sub> and HDL<sub>3</sub>. *Endocrinology* 131:2805-2811; 1992.
19. Klein HG, Lohse P, Duverger N, Albers JJ, Rader DJ, Zech LA, Santamarina-Fojo S, Brewer HB Jr. Two different allelic mutations in the lecithin-cholesterol acyltransferase (LCAT) gene resulting in classic LCAT deficiency: LCAT (Tyr<sup>83</sup>->Stop) and LCAT (Tyr<sup>156</sup>->Asn). *J Lipid Res* 34:49-58; 1993.
20. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in Lp(a) concentrations among individuals with the same apo(a) isoform is determined by the rate of Lp(a) production. *J Clin Invest* 91:443-447; 1993.
21. Rader DJ, Schaefer JR, Lohse P, Verges B, Kindt M, Zech LA, Steinmetz A, Brewer HB Jr. Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoform. *J Clin Invest* 92:1009-1017; 1993.

22. Rader DJ, Brewer HB Jr. Abetalipoproteinemia: New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. *JAMA* 270:865-869; 1993.
23. Wanner C, Rader DJ, Bartens W, Kraemer J, Brewer HB Jr, Schollmeyer P, Wieland H. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. *Ann Int Med* 199:263-269; 1993.
24. Emmerich J, Verges B, Tauveron I, Rader DJ, Santamarina-Fojo S, Schaefer J, Ayault-Jarrier M, Thieblot P, Brewer HB Jr. Familial high density lipoprotein deficiency due to marked hypercatabolism of normal apolipoprotein A-I. *Arteriosclerosis and Thrombosis* 13:1299-1306; 1993.
25. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wagner-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ, Aggerbeck LP, Gregg RE, Gordon DA, Wetterau JR. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinemia. *Nature* 365:65-69; 1993.
26. Rader DJ, Schaefer JR, Lohse P, Ikewaki K, Thomas F, Harris WA, Zech LA, Dujovne CA, Brewer HB Jr. Increased production of apolipoprotein A-I associated with elevated levels of high density lipoproteins and apolipoprotein A-I in a patient with familial hyperalphalipoproteinemia. *Metabolism* 42:1429-1434; 1993.
27. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer J, Ishikawa T, Fairwell T, Zech L, Nakamura H, Nagano M, Brewer HB Jr. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. *J Clin Invest* 92:1650-1658; 1993.
28. Ikewaki K, Rader DJ, Schaefer J, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer labeling methods. *J Lipid Res* 34:2207-2215; 1993.
29. Rader DJ, Ikewaki K, Duverger N, Feuerstein I, Zech LA, Connor W, Brewer HB Jr. Markedly decreased plasma high density lipoprotein levels without premature coronary atherosclerosis caused by rapid catabolism of apolipoproteins A-I and A-II. *Lancet* 342:1455-1458; 1993.
30. Duchateau P, Rader DJ, Duverger N, Theret N, De Geitere C, Brewer HB Jr, Fruchart JC, Castro G. Tangier disease: isolation and characterization of LpA-I, LpA-I:A-II, LpA-II, and LpA-IV particles from plasma. *Biochim Biophys Acta* 1182:30-36; 1993.
31. Duverges N, Rader DJ, Duchateau P, Fruchart JC, Castro G, Brewer HB Jr. Biochemical characterization of the three major subclasses of lipoprotein A-I (LpA-I) preparatively isolated from human plasma. *Biochemistry* 32:12372-12379; 1993.
32. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, Clerc M, Dumon MF, Fairwell T, Zech L, Santamarina-Fojo S, Brewer HB Jr. Rapid catabolism of apolipoprotein A-II and high density lipoproteins containing apoA-II in classic LCAT deficiency and fish-eye disease. *J Clin Invest* 93:321-330; 1994.
33. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. *Ann Int Med* 120:1012-1025; 1994.
34. Sack M, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. *Lancet* 343:269-270; 1994.
35. Usher DC, Swanson C, Rader DJ, Krämer J, Brewer HB Jr. A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies. *Chemistry and Physics of Lipids* 67/68:243-248; 1994.
36. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. *J Clin Invest* 93:2758-2763; 1994.
37. Traber MG, Rader DJ, Acuff R, Brewer HB Jr., Kayden HJ. Discrimination between RRR- and all racemic-alpha-tocopherols labeled with deuterium by patients with abetalipoproteinemia. *Atherosclerosis* 108:27-37; 1994.
38. Bartens W, Rader DJ, Talley G, Brewer HB Jr. Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. *Atherosclerosis* 108:149-157; 1994.
39. Duverger N, Rader DJ, Brewer HB Jr. Distribution of subclasses of human HDL containing apolipoprotein A-I without apolipoprotein A-II (LpA-I) in normolipidemic men and women. *Arteriosclerosis and Thrombosis* 14:1594-1599; 1994.
40. Ikewaki K, Rader DJ, Zech LA, Brewer HB Jr. Abnormal in vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. *J Lipid Res* 35:1809-1819; 1994.
41. Benvenga S, Cahnmann HJ, Rader DJ, Kindt M, Facchiano A, Robbins J. Thyroid hormone binding to isolated human apolipoproteins A-II, C-I, C-II, and C-III: homology in thyroxine binding sites. *Thyroid* 4:261-269; 1994.

42. Verges B, Rader DJ, Schaefer J, Zech L, Kindt M, Fairwell T, Gambert P, Brewer HB Jr. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope study. *J Lipid Res* 35:2280-2291; 1994.
43. Gorin MB, Paul TO, Rader DJ. Angioid streaks associated with abetalipoproteinemia. *Ophthalmic Genetics* 15:151-159; 1994.
44. Gilligan D, Sack M, Guetta V, Casino P, Quyyumi A, Rader DJ, Panza J, Cannon RO III. The effect of antioxidant vitamins on low-density lipoprotein oxidation and impaired endothelium-dependent vasodilatation in patients with hypercholesterolemia. *J Am Coll Card* 24:1611-1617; 1994.
45. Duverger N, Rader DJ, Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Nagano M, Nakamura H, Brewer HB Jr. Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. *E J Biochem* 227:123-129; 1995.
46. Skarlatos S, Duverger N, Rader DJ, Kruth H. Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II. *Biochim Biophys Acta* 1270:19-25; 1995.
47. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB Jr. The LDL receptor is not required for normal catabolism of Lp(a) in humans. *J Clin Invest* 95:1403-1408; 1995.
48. Ikewaki K, Zech L, Kindt M, Brewer HB Jr, Rader DJ. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. *Arterio Thromb Vasc Biol* 15:306-312; 1995.
49. Ricci B, Sharp D, O'Rourke E, Kienzle B, Blinderman L, Gordon D, Smith-Monroy C, Robinson G, Gregg R, Rader D, Wetterau J. A 30 amino acid truncation of the microsomal triglyceride transfer protein large subunit disrupts its interaction with protein disulfide isomerase and causes abetalipoproteinemia. *J Biol Chem* 270:14281-14285; 1995.
50. Bartens W, Rader DJ, Talley G, Kindt M, Brewer HB Jr. Lipoprotein(a) in patients with combined hyperlipidemia: effect of triglycerides. *E J Clin Invest* 25:647-653; 1995.
51. Aguié G, Rader DJ, Clavey V, Traber M, Torpier G, Kayden H, Fruchart JC, Brewer HB Jr, Castro G. Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia: identification and characterization. *Atherosclerosis* 118:183-191; 1995.
52. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech L, Nagano M, Nakamura H, Brewer HB Jr, Rader DJ. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. *J Clin Invest* 96:1573-1581; 1995.
53. Grossman M, Rader DJ, Muller D, Kolansky D, Kozarsky K, Clark BJ, Stein E, Lupien P, Brewer HB Jr, Raper S, Wilson JM. A pilot study of *ex vivo* gene therapy for homozygous familial hypercholesterolemia. *Nature Medicine* 1:1148-1154; 1995.
54. Jamieson D, Usher D, Rader DJ, Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels: a potential role for endothelial cells in lesion formation. *Am J Pathol* 147:1567-1574; 1996.
55. Raper SE, Grossman M, Rader DJ, Thoene JG, Clark BJ, Kolansky DM, Muller D, Wilson JM. Safety and feasibility of liver-directed *ex vivo* gene therapy for homozygous familial hypercholesterolemia. *Annals of Surgery* 223:116-126; 1996.
56. Ikewaki K, Zech L, Brewer HB Jr, Rader DJ. ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. *J Lipid Res* 37:399-407; 1996.
57. Eder A, Rader DJ. LDL-Apheresis for severe refractory dyslipidemia. *Today's Therapeutic Trends* 14:165-179; 1996.
58. Rader DJ, Ikewaki K. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. *Curr Opin Lipidology* 7:117-123; 1996.
59. Tsukamoto K, Smith P, Glick J, Rader DJ. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE deficient mice. *J Clin Invest* 100:107-114; 1997.
60. Higazi A, Lavi E, Ulrich A, Jamieson D, Rader DJ, Usher D, Cain W, Ganz T, Cines D. Defensin stimulates the binding of lipoprotein(a) to human vascular endothelial and smooth muscle cells. *Blood* 89:4290-4298; 1997.
61. Webb NR, de Beer MC, van der Westhuyzen DR, Kindy MS, Banka CL, Tsukamoto K, Rader DJ, de Beer FC. Adenoviral vector-mediated over-expression of serum amyloid A in apoA-I deficient mice. *J Lipid Research* 38:1583-1590; 1997.
62. Rader DJ. Gene therapy for atherosclerosis. *International Journal of Clinical and Laboratory Research* 27:35-43; 1997.

63. Tsukamoto K, Rader DJ. Gene therapy for atherosclerotic disease: future prospects. *Cardiovascular Risk Factors* 7:129-137; 1997.
64. Daugherty A, Pure E, Butteiger D, Chen S, Leferovich J, Roselaar S, Rader DJ. The effect of total lymphocyte deficiency on extent of atherosclerosis in apolipoprotein E<sup>-/-</sup> mice. *J Clin Invest* 100:1575-1580; 1997.
65. Tsukamoto K, Hiester K, Smith P, Usher D, Glick J, Rader DJ. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. *J Lipid Research* 38:1869-1876; 1997.
66. Chang G, DeNofrio D, Desai S, Kelley MP, Rader DJ, Acker MA, Loh E. Lipoprotein(a) levels and heart transplantation atherosclerosis. *Am Heart J* 136:329-334; 1998.
67. Kindy MS, Rader DJ. Reduction in amyloid A amyloid formation in apolipoprotein E-deficient mice. *Am J Pathol* 152:1387-1395; 1998.
68. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation *in vivo* and reduces atherosclerosis in apoE deficient mice. *Nature Medicine* 4:1189-1192; 1998.
69. Rader DJ, FitzGerald GA. State of the art: Atherosclerosis in a limited edition. *Nature Medicine* 4:899-900; 1998.
70. Traber M, Rader DJ, Acuff R, Ramakrishnan R, Brewer HB Jr, Kayden H. Vitamin E dose response studies in humans using deuterated RRR- $\alpha$ -tocopherol. *A J Clin Nutr* 68:847-853; 1998.
71. Rader DJ. Gene therapy for atherosclerosis. *Molecular Therapeutics* 1:680-689; 1998.
72. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader DJ, Kapoor S, Lawson J, FitzGerald GA. Increased biosynthesis of distinct F2 isoprostanes in hypercholesterolemia. *Circulation* 98:2822-2828; 1998.
73. Hosoi H, Webb NR, Glick J, Purdom MS, de Beer FC, Rader DJ. Expression of serum amyloid A protein in the absence of the acute phase response is not sufficient to reduce HDL cholesterol or apoA-I levels in mice. *J Lipid Res* 40:648-653; 1999.
74. Jaye M, Lynch KL, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ. A novel endothelial-derived lipase that modulates HDL metabolism. *Nature Genetics* 21:424-428; 1999.
75. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. *Mayo Clinic Proceedings*. 74:243-52, 1999.
76. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Witztum JL, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. *J Clin Invest* 103:1597-1604; 1999.
77. Rader DJ. Pathophysiology and management of low high-density lipoprotein cholesterol. *The American Journal of Cardiology* 83:22F-24F; 1999.
78. Rader DJ, Haffner SM. Role of fibrates in the management of hypertriglyceridemia. *The American Journal of Cardiology* 83:30F-35F; 1999.
79. Tsukamoto K, Tangirala R, Chun SH, Pure' E, Rader DJ. Rapid regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein E in apoE deficient mice. *Arterio Thromb Vasc Biol* 19:2162-2170, 1999.
80. Rader DJ, Tietge U. Gene Therapy for Dyslipidemia. *Current Atherosclerosis Reports* 1:58-69; 1999.
81. Rader DJ, Meagher E. Lipid lowering drug therapy in primary prevention: who should be treated? *Preventive Cardiology* 2:105-114, 1999.
82. Rader DJ. Noninvasive procedures for subclinical atherosclerosis risk assessment. *The American Journal of Medicine* 107:25S-27S, 1999.
83. Tangirala R, Tsukamoto K, Chun SH, Usher D, Pure' E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. *Circulation* 100:1816-1822, 1999
84. Hobbs HH, Rader DJ. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. *J Clin Invest* 104:1015-1018; 1999.
85. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, Nestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. *J Clin Endo Metab* 84:3896-902, 1999.
86. Tietge U, Tsukamoto K, Maugeais C, Bakillah A, Hussain M, Rader DJ. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased *in vivo* production of VLDL triglycerides and apolipoprotein B. *J Lipid Res* 40:2134-2139; 1999.

87. Tietge UJF, Maugeais C, Cain W, Grass D, Glick J, deBeer FC, Rader DJ. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of HDL cholesteryl ester and apolipoprotein A-I. *J Biol Chem* 275:10077-10084; 1999
88. Tsukamoto K, Maugeais C, Glick JM, Rader DJ. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE deficient mice. *J Lipid Res* 41:253-259; 2000.
89. Tsukamoto K, Tangirala RK, Chun S, Usher D, Pure' E, Rader DJ. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis in LDL receptor deficient mice. *Molecular Therapy* 1:189-194; 2000.
90. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Hepatic overexpression of the HDL receptor SR-BI inhibits atherosclerosis despite reducing HDL cholesterol levels in mice. *Arterio Thromb Vasc Biol* 20:721-727; 2000.
91. Rader DJ, Maugeais C. Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. *Molecular Medicine Today* 6:170-175; 2000.
92. DeNofrio D, Desai S, Rader DJ, Chang G, Kelly MP, Acker MA, Loh E. Changes in lipoprotein(a) concentrations following orthotopic heart transplantation. *Am Heart J* 139:729-733; 2000.
93. Rader DJ and Jaye M. Endothelial lipase: a new member of the triglyceride lipase gene family. *Curr Opin Lipidology* 11:141-148; 2000.
94. Rader DJ and Pure' E. Genetic susceptibility to atherosclerosis: insights from mice. *Circulation Research* 86:1013-1015; 2000.
95. Kawashiri M, Maugeais C, Rader DJ. High density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. *Curr Atherosclerosis Reports* 2:363-372; 2000.
96. Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao GP, Wilson JM. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expression VLDL receptor. *Molecular Therapy* 2:256-261; 2000.
97. Maugeais C, Tietge UJF, Tsukamoto K, Glick JM, Rader DJ. Hepatic apoE expression promotes VLDL-apoB production in mice. *J Lipid Research* 41:1673-1679; 2000.
98. Higazi AA, Nassar T, Ganz T, Rader DJ, Udassin R, Bdeir K, Hiss E, Sachais BS, Williams KJ, Leitersdorf E, Cines DB. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. *Blood*. 96:1393-8; 2000.
99. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock JM, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow C, Chao YS, Rader DJ, Wright SD, Pure E. Deficiency in inducible nitric oxide synthase (iNOS) results in reduced atherosclerosis in apoE-deficient mice. *J Immunology* 165:3430-3435; 2000.
100. Rader DJ, Dugi KA. The endothelium and lipoproteins: insights from recent cell biology and animal studies. *Seminars in Thrombosis and Hemostasis* 26:521-528; 2000.
101. Dugi KA, Rader DJ. The endothelium and lipoproteins: a clinical perspective. *Seminars in Thrombosis and Hemostasis* 26:529-536; 2000.
102. Rader DJ. Inflammatory markers of coronary risk. *New Engl J Med* 343:1179-1182; 2000.
103. Tangirala RK, Pratico D, FitzGerald GA, Chun S, Tsukamoto K, Maugeais C, Usher DC, Pure' E, Rader DJ. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. *J Biol Chem* 276:216-266; 2001.
104. Tietge UJF, Sun G, Czarniecki S, Yu QC, Lohse P, Du H, Grabowski GA, Glick JM, Rader DJ. Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase. *Human Gene Therapy* 12:279-289; 2001.
105. Wolfe ML, Vartanian SF, Ross JL, Bansavich LL, Mohler ER III, Meagher E, Friedrich CA, Rader DJ. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. *Am J Cardiol* 87:476-479; 2001.
106. Szapary PO and Rader DJ. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. In: *Curr Opin in Pharm* 1:113-120; 2001
107. Kawashiri M, Zhang Y, Usher D, Reilly M, Pure' E, Rader DJ. Effects of co-expression of the LDL receptor on cholesterol metabolism and atherosclerosis in LDLreceptor-deficient mice. *J Lipid Res* 42:943-950; 2001.
108. Valdes AM, Wolfe M, Tate HC, Rut A, Rader DR. Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: the Study of the Inherited Risk of Coronary Atherosclerosis. *J Invest Med* 49: 353-361:2001.

109. Cyrus T, Pratico D, Zhao L, Witztum J, Rader DJ, Rokach J, FitzGerald G, Funk C. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. *Circulation* 103:2277-2282; 2001.
110. Reilly MP, Rader DJ. Clinical decision-making in the management of lipid disorders. *Disease Management and Clinical Outcomes* 3:30-37; 2001.
111. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assosian RK, Rader DJ, Pure E. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and activation of vascular cells. *J Clin Invest* 108:1031-1040; 2001
112. Meagher E, Rader DJ. Antioxidant therapy and atherosclerosis: animal and human studies. *Trends Cardiovasc Med*. 11:162-5; 2001.
113. Snyder PJ, Peachey H, Berlin JA, Rader DJ, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna J, Strom BL. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. *Am J Med* 111:255-260; 2001
114. Thompson PD, Rader DJ. Does exercise increase HDL cholesterol in those who need it the most? *Arterio Thromb Vasc Biol*. 21: 1097-1098; 2001
115. Grundy SM, D'Agostino RB, Mosca L, Burke GL, Wilson PWF, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies. *Circulation* 104: 491-496; 2001
116. Rader DJ. A new feature on the cholesterol-lowering landscape. *Nature Med*. 7: 1282-1284; 2001
117. Rader DJ. Gene therapy for familial hypercholesterolemia. *Nutr Metab Cardiovasc Dis. Suppl* 5:40-4; 2001.
118. Cuchel M, Rader DJ. The role of high-density lipoproteins in thrombosis. *The Scientific World*. 2: 89-95; 2002.
119. Millar JS, Maugeais C, Fuki IV, Rader DJ. Normal production rate of apolipoprotein B in LDL receptor-deficient mice. *Arterio Thromb Vasc Biol*. 22: 989-994; 2002
120. Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. *Trends in Endo & Metab* 13: 174-178; 2002
121. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. *J Lipid Res*. 43: 921-929; 2002
122. Tietge UJF, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ. Human secretory phospholipase A2 (sPLA2) mediates decreased plasma levels of HDL-cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. *Arterio Thromb Vasc Biol* 22:1213-1218; 2002
123. Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. *J Biol Chem* 277:35350-6; 2002
124. Jin W, Broedl U, Monajemi H, Glick JM, Rader DJ. Lipase H, a new member of the triglyceride lipase gene family synthesized in the intestine. *Genomics*: 80: 268-273; 2002
125. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identification of genetic variants in endothelial lipase in persons with elevated high density lipoprotein cholesterol. *Circulation*: 106: 1321-1326; 2002
126. Cuchel M, Wolfe ML, DeLemos AS, Rader DJ. The frequency of the cholesteryl ester transfer protein – *TaqI* B2 allele is lower in African Americans than in Caucasians. *Atherosclerosis*:163: 169-174; 2002
127. Epstein JA, Rader DJ, Parmacek MS. Cardiovascular disease in the postgenomic era – lessons learned and challenges ahead. *Endocrinology*: 143: 1-6; 2002
128. Kawashiri M, Zhang Y, Puré E, Rader DJ. Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor mice. *Atherosclerosis*: 165:15-22; 2002
129. Valdes AM, Wolfe ML, O'Brien EJ, Spurr NK, Geffer W, Rut A, Groot PHE, Rader DJ. Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. *Arterio Thromb Vasc Biol*: 22:1924-1928; 2002
130. Rader DJ. High-density lipoproteins and atherosclerosis. *Am J Cardiol*: 90 (suppl.):62I-70I; 2002
131. Yu YH, Zhang Y, Oelkers P, Sturley SL, Rader DJ, Ginsberg HN. Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. *J Biol Chem* 277:50876-84; 2002
132. Wolfe ML, Iqbal N, Geffer W, Mohler ER, Rader DJ, Reilly M. Coronary artery calcification at electron beam CT is increased in asymptomatic type 2 diabetics independent of traditional risk factors. *J Cardiovasc Risk*; 9:369-76; 2002

133. Ikewaki K, Zech LA, Brewer HB Jr, Rader DJ. Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects. *J Lab Clin Med*; 140: 1924-1928; 2002
134. Rader DJ, Davidson M, Caplan R, Pears J. Lipid and apolipoprotein in ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. *Am J Cardiol* 91:20C-23C; discussion 23C-24C; 2003
135. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels *in vivo*. *J Clin Invest* 111: 357-362; 2003.
136. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. *Arterioscler Thromb Vasc Biol* 23:160-7; 2003
137. Jin W, Gwo-Shing S, Marchadier D, Octavani E, Glick JM, Rader DJ. Endothelial cells secrete triglyceride lipase and phospholipase activities due to endothelial lipase in response to inflammatory cytokines. *Circ Res* 92: 644-650; 2003
138. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. *Proc Natl Acad Sci*, Tal 100:2730-5; 2003.
139. Rader DJ. Interrelationships between the metabolic syndrome, inflammation, and HDL metabolism. *Cardiology Review* 20: 12-15; 2003
140. Rader DJ. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. *Am J Cardiol* 91:18E-23E; 2003.
141. Tietge UJF, Maugeais C, Cain W, Rader DJ. Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. *Am J Physiol Endocrinol Metab* 285:E403-11; 2003
142. Foster GD, Wyatt HR, Hill J, McGuckin BG, Brill C, Mohammed BS, Szapary P, Rader DJ, Edman JS, Klein S. A multicenter, randomized, controlled trial of a low-carbohydrate diet for obesity. *N England J Med* 348: 2082-2092; 2003
143. Tietge UJF, Kozarsky KF, Donahee MH, Rader DJ. A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver. *J Gene Med* 5:567-675; 2003
144. Rashid S, Trinh DK, Uffelman KD, Cohn JS, Rader DJ, Lewis GF. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native HDL apolipoprotein A-I. *Circulation* 107:3066-72; 2003
145. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *J Clin Invest* 111: 1795-1803; 2003
146. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. *Arch Intern Med* 163: 1155-1164; 2003
147. Rader DJ. Therapy to reduce risk of coronary heart disease. *Clin Cardiol* 26: 2-8; 2003
148. Kothapalli D, Stewart SA, Smyth EM, Azonobi I, Rader DJ, Puré E, Assoian RK. Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin A gene expression. *Mol Pharmacol* 64:1-10; 2003
149. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? *Circulation* 108: 1546-51; 2003
150. Szapary PO, Wolfe ML, Bloedon LT, Cucchiaria AJ, DerMarderosian AH, Cirigliano MD, Rader DJ. Guggulipid for the treatment of hypercholesterolemia: a randomized, controlled trial. *JAMA* 290: 765-72; 2003
151. Zhang Y, Zanotti I, Reilly M, Glick JM, Rothblat GH, Rader DJ. Overexpression of apoA-I promotes reverse transport of cholesterol from macrophages to feces. *Circulation* 108: 661-3; 2003
152. Reilly MP, Wolfe ML, Localico AR, Rader DJ. C-reactive protein and coronary artery calcification: the study of inherited risk of coronary atherosclerosis. *Arterio Thromb Vasc Biol* 23:1851-1856; 2003
153. Maugeais C, Tietge UJF, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM, Rader DJ. Dose-dependent acceleration of HDL catabolism by endothelial lipase. *Circulation* 108:2121-2126; 2003
154. Fuki IV, Blanchard N, Jin W, Marchadier D, Millar JS, Glick JM, Rader DR. Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via HSPG-mediated pathway. *J Biol Chem* 278: 34331-8; 2003
155. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. *Am J Cardiol* 92: 42J-49J; 2003

156. Duong M, Psaltis M, Rader DJ, Marchadier D, Barter PJ, Rye KA. Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. *Biochemistry* 42: 13778-13785; 2003
157. Rosas S, Szapary P, Rader DJ. Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation. *Cardiol Clin* 21:377-392; 2003
158. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. *JAMA* 290:2322-2324; 2003
159. Moore RE, Kawashiri MA, Kitajima K, Secreto A, Millar JS, Pratico D, Rader DJ. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. *Arterio Thromb Vasc Biol* 23:1914-1920; 2003
160. Broedl UC, Maugeais C, Marchadier D, Glick JM, Rader DJ. Effects of nonlipolytic ligand function of endothelial lipase on high-density lipoprotein metabolism in vivo. *J Biol Chem* 278:40688-40693; 2003
161. Cuchel M, Rader DJ. Genetics of increased HDL cholesterol levels: insights into the relationship between HDL metabolism and atherosclerosis. *Arterio Thromb Vasc Biol* 23:1710-1712; 2003
162. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. *JAMA* 290:2292-300; 2003
163. Jacoby DS, Mohler III ER, Rader DJ. Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. *Curr Atheroscler Rep* 6:20-6; 2004
164. Caiazza D, Jahangiri A, Rader DJ, Marchadier D, Rye KA. Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. *Biochemistry* 43:11898-905; 2004
165. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. *Am J Med* 117:398-405; 2004
166. Wolfe ML, Rader DJ. Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. *Circulation* 110:1338-40; 2004
167. Rader DJ. Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein. *Curr Atheroscler Rep* 6:398-405; 2004
168. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, John N, Schmidt S, Spanbroek R, Lotzer K, Huang L, Cui J, Rader DJ, Evans JF, Habenicht AJ, Funk CD. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. *Nat Med* 10:966-73; 2004
169. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. *Circulation* 110:803-9; 2004
170. Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? *Am Heart J* 148:211-21; 2004
171. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. *J Clin Endocrinol Metab* 89:3872-8; 2004
172. Badellino KO, Rader DJ. The role of endothelial lipase in high-density lipoprotein metabolism. *Curr Opin Cardiol* 19:392-5; 2004
173. Ikewaki K, Cain W, Thomas F, Shamburek R, Zech LA, Usher D, Brewer HB Jr, Rader DJ. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency. *J Lipid Res* 45:1302-11; 2004
174. Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. *Trends Cardiovasc Med* 14:202-6; 2004
175. Broedl UC, Maugeais C, Millar JS, Jin W, Moore RE, Fuki IV, Marchadier D, Glick JM, Rader DJ. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. *Circ Res* 94:1554-61; 2004
176. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med* 350:1505-15; 2004
177. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 350:1495-504; 2004



178. Reilly MP, Wolfe ML, Localio AR, Rader DJ. Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. *Atherosclerosis* 173:69-78; 2004
179. Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, Schneck DW. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. *Coron Artery Dis* 15:115-23; 2004
180. Kothapalli D, Fuki I, Ali K, Stewart SA, Zhao L, Yahil R, Kwiatkowski D, Hawthorne EA, FitzGerald GA, Phillips MC, Lund-Katz S, Pure E, Rader DJ, Assoian RK. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. *J Clin Invest* 113:609-18; 2004
181. Yancey PG, Kawashiri MA, Moore R, Glick JM, Williams DL, Connelly MA, Rader DJ, Rothblat GH. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. *J Lipid Res* 45:337-46; 2004
182. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. *Science* 10;306:1954-7; 2004
183. Broedl UC, Jin W, Fuki IV, Glick JM, Rader DJ. Structural basis of endothelial lipase tropism for HDL. *FASEB J* 18:1891-3; 2004
184. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chretien M, Prat A, Seidah NG. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *J Biol Chem* 19;279:48865-75; 2004
185. Miller GC, Long CJ, Bojilova ED, Marchadier D, Badellino KO, Blanchard N, Fuki IV, Glick JM, Rader DJ. Role of N-linked glycosylation in the secretion and activity of endothelial lipase. *J Lipid Res* 45:2080-7; 2004
186. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An Inflammatory Cascade Leading to Hyperresistinemia in Humans. *PLoS Med* 1:e45; 2004
187. Reilly MP, Wolfe ML, Dykhouse J, Reddy K, Localio AR, Rader DJ. Intercellular adhesion molecule 1 (ICAM-1) gene variant is associated with coronary artery calcification independent of soluble ICAM-1 levels. *J Invest Med* 52:515-22; 2004
188. Bastone L, Reilly M, Rader DJ, Foulkes AS. MDR and PRP: a comparison of methods for high-order genotype-phenotype associations. *Hum Hered* 58:82-92; 2004
189. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. *J. Lipid Res* 46:896-903; 2005
190. Foulkes AS, Reilly M, Zhou L, Wolfe M, Rader DJ. Mixed modeling to characterize genotype-phenotype associations. *Stat Med* 24:775-89; 2005
191. Rader DJ. Novel approaches to the treatment of dyslipidemia. *Arterio Thromb Vasc Bio* 25:480-81; 2005
192. Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC, Boston RC, Tada N, Mochizuki S, Defesche JC, Wilson JM, Rader DJ. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. *Arterio Thromb Vasc Bio* 25:560-5; 2005
193. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. *Circulation* 111:932-9; 2005
194. Ky B, Rader DJ. The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. *Clin Cardiol* 38:67-70; 2005
195. Kratky D, Zimmermann R, Wagner EM, Strauss JG, Jin W, Kostner GM, Haemmerle G, Rader DJ, Zechner R. Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. *J Clin Invest* 115:161-7; 2005
196. Rader DJ. Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm. *Neth J Med* 63:2-3; 2005
197. Sovic A, Panzenboeck U, Wintersperger A, Kratzer I, Hammer A, Levak-Frank S, Frank S, Rader DJ, Malle M, Sattler W. Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier. *J. Neurochem* 10.1111/j:1471-4159; 2005
198. Sachais BS, Katz J, Ross J, Rader DJ. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. *J Clin Apher* 20:252-5; 2005
199. Duffy D, Rader DJ. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. *Curr Opin Cardiol* 20:301-306; 2005
200. Rosas SE, Mensah K, Weinstein RB, Bellamy SL, Rader DJ. Coronary artery calcification in renal transplant recipients. *Am J Transplant* 5:1942-7; 2005

201. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circ Res* 96:1221-32; 2005
202. Dunbar RL, Rader DJ. Current drug options for raising HDL cholesterol. *Curr Treat Options Cardiovasc Med* 7:15-23; 2005
203. Rader DJ, Pure' E. Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell? *Cell Metab* 1:223-230; 2005
204. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Bjorkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. *Arterioscler Thromb Vasc Biol* 25:1057-64; 2005
205. Broedl UC, Rader DJ. Gene therapy for lipoprotein disorders. *Expert Opin Biol Ther* 5:1029-38; 2005
206. Lehrke M, Lebherz C, Millington SC, Guan HP, Millar J, Rader DJ, Wilson JM, Lazar MA. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. *Cell Metab* 1:297-308; 2005
207. Kitajima K, Marchadier DH, Burstein H, Rader DJ. Persistent liver expression of murine apoA-I using vectors based on adeno-associated viral vectors serotypes 5 and 1. *Atherosclerosis* Aug 11; [Epub ahead of print]
208. Jin W, Fuki IV, Seidah NG, Benjannet S, Glick JM, Rader DJ. Proprotein convertases are responsible for proteolysis and inactivation of endothelial lipase. *J Biol Chem* 280:36551-36559; 2005
209. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ. Lipoprotein(a) is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein(a). *J Lipid Res* 46:2681-91; 2005
210. Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ. Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation. *Circ Res* 97:763-71; 2005
211. Reilly M, Foulkes AS, Wolfe ML, Rader DJ. Higher-order lipase gene association with plasma triglycerides. *J Lipid Res* 46:1914-22; 2005
212. Madaio MP, Ahima RS, Meade R, Rader DJ, Mendoza A, Peng M, Tomaszewski JE, Hancock WW, Gasser DL. Glomerular and Tubular Epithelial Defects in *kd/kd* Mice Lead to Progressive Renal Failure. *Am J Nephrol* 25:604-610; 2005
213. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. *J Clin Invest* 115:2870-4; 2005
214. Rader DJ. Gain-of-function mutations and therapeutic implications: lipoprotein lipase S447X to the rescue. *ATVB*. 25:2018-9; 2005
215. Ali K, Middleton M, Pure E, Rader DJ. Apolipoprotein E suppresses the type I inflammatory response in vivo. *Circ Res* 97:922-927; 2005
216. Broedl UC, Jin W, Marchadier D, Secreto A, Rader DJ. Tissue-specific expression pattern of human endothelial lipase in transgenic mice. *Atherosclerosis* 181:271-274; 2005
217. Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. *J Lipid Res* 46:2023-2028; 2005
218. Li Z, Qiao H, Lebherz C, Choi SR, Zhou X, Gao G, Kung HF, Rader DJ, Wilson JM, Glickson JD and Zhou R. Creatine Kinase, a Magnetic Resonance Detectable Marker Gene for Quantification of Liver-Directed Gene Transfer. *Hum Gene Ther* 16:1429-1438; 2005
219. Zhao L, Pratico D, Rader DJ, Funk CD. 12/15-Lipoxygenase gene disruption and Vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. *Prostaglandins Other Lipid Mediat* 78:185-193; 2005
220. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, Gretarsdottir S, Magnusson KP, Gudmundsson G, Hicks A, Jonsson T, Grant SFA, Sainz J, O'Brien SJ, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Levey AI, Abramson JL, Reilly MP, Vaccarino V, Wolfe ML, Gudnason V, Quyyumi AA, Topol EJ, Rader DJ, Thorgeirsson G, Gulcher JR, Hakonarson H, Kong A, Stefansson K. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. *Nat Gen* 38:68-74; 2006
221. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer, JT, Rothblat GH, Rader DJ. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. *Circulation* 113:90-97; 2006

222. Seetharam D, Chieko M, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, Rader DJ, Shaul PW. HDL promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. *Circ Res* 98:63-72; 2006
223. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ. Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients with Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome. *ATVB* 26:624-630; 2006
224. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis. *PLoS Med* 3:e22; 2006
225. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ. Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. *ATVB* 26:182-188; 2006
226. Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. *ATVB*; 2006 *in press*
227. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. *Circulation* 113:1140-1150; 2006
228. Majdalawieh A, Zhang L, Fuki IV, Rader DJ, Ro HS. Adipocyte enhancer-binding 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. *Proc Natl Acad Sci* 103:2346-2351; 2006
229. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leucocyte adhesion. *Circ Res* 98:490-498; 2006
230. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Gen* 38:230-323; 2006
231. Duffy D, Rader DJ. High-density lipoprotein cholesterol therapies: the next frontier in lipid management. *J Cardiopulm Rehabil* 26:1-8; 2006
232. Griffon N, Budreck EC, Long CJ, Broedl UC, Marchadier DH, Glick JM, Rader DJ. Substrate specificity of lipoprotein lipase and endothelial lipase: studies of lipid chimeras. *J Lipid Res* 2006
233. Reilly M, Rader DJ. Apolipoprotein E and coronary disease: a puzzling paradox. *PLoS Med* 3:e258; 2006
234. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? *Circulation* 113:2548-2555; 2006
235. Kitajima K, Marchadier DH, Miller GC, Gao GP, Wilson JM, Rader DJ. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. *ATVB* 26:1852-7; 2006
236. Qasim A, Rader DJ. Human genetics of variation in high-density lipoprotein cholesterol. *Curr Athero Rep* 8:198-205; 2006
237. Broedl UC, Jin W, Fuki IV, Millar JS, Rader DJ. Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. *J Lipid Res* 47:2191-7; 2006
238. Paradis ME, Badellino KO, Rader DJ, Tchernof A, Richard C, Luu-The V, Deshaies Y, Bergeron J, Archer WR, Couture P, Bergeron N, Lamarche B. Visceral adiposity and endothelial lipase. *J Clin Endocrin Metab* 91:538-43; 2006
239. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. *J Clin Invest* 116:3090-100; 2006
240. Paradis ME, Badellino KO, Rader DJ, Deshaies Y, Couture P, Archer WR, Bergeron N, Lamarche B. Endothelial lipase is associated with inflammation in humans. *J Lipid Res* 47:2808-13; 2006
241. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Schafer H, Faruque M, Doumatey A, Zhou J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Sigurdsson G, Hebebrand J, Pedersen O, Thorsteinsdottir U, Gulcher JR, Kong A, Rotimi

C, Stefansson K. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. *Nat Genet* 2007

#### Editorials and Book Chapters

1. Schaefer JS, Rader DJ, Gregg RE, Fairwell T, Zech LA, Kindt MR, Benson MD, Brewer HB Jr. *In vivo* protein metabolism utilizing stable isotopes and mass spectrometry: a new approach to the study of mutant proteins in humans. *Trans Assoc Am Physicians* 103:187-194;1990.
2. Brewer HB Jr, Rader DJ, Fojo SS, Hoeg JM. Frontiers in the analysis of HDL structure, function, and metabolism. In: *Disorders of HDL*. Carlson LA (ed), Smith-Gordan, pp. 51-58; 1990.
3. Brewer HB Jr, Rader DJ, Hoeg JM, Mann A, Tennyson G. Recent advances in lipoprotein metabolism and the genetic dyslipoproteinemias. *Adv Exp Med Biol* 285:237-244; 1991.
4. Zech LA, Rader DJ, Greif PC. Berman's simulation analysis and modeling. *Adv Exp Med Biol* 285:188-199; 1991.
5. Brewer HB Jr and Rader DJ. HDL: Structure, Function and Metabolism. *Prog. Lipid Res* 30:139-144; 1991.
6. Rader DJ, Ikewaki K, Schaefer J, Brewer HB Jr. Metabolism of HDL particles LpA-I and LpA-I,A-II in normal and hyperalphalipoproteinemic subjects. In: *Atherosclerosis Reviews: High density lipoproteins - Pathophysiology and clinical relevance*. Catapano A, Bernini F, and Corsini A (eds), Raven Press, New York, New York, pp. 43-55; 1993.
7. Rader DJ, Patterson A, Eggerman T, Hoeg JM, Brewer HB Jr. Apolipoprotein B mRNA editing: modulation and clinical implications. In: *Hormones in lipoprotein metabolism*. Steinmetz A (ed), Springer-Verlag, Heidelberg, Germany, pp. 17-21; 1993.
8. Rader DJ and Brewer HB Jr. Lipids, Apolipoproteins, and Lipoproteins. In: *Genetic Factors in Coronary Heart Disease*. Goldbaurt U, de Faire U, Berg K (eds), Kluwer Academic Publishers, Dordrecht, The Netherlands; pp. 83-104; 1994.
9. Rader DJ and Wilson JM. Gene Therapy for Lipid Disorders. In: *Molecular Cardiovascular Medicine*. Haber E (ed), Scientific American Medicine, New York; pp. 97-114; 1995.
10. Rader DJ. Genetic Dyslipoproteinemias: Inborn Errors of Lipoprotein Metabolism. In: *A Physician's Guide to the Laboratory Diagnosis of Inherited Metabolic Disease*. Blau N, Duran M, Blaskovics M (eds), Chapman and Hall, London; 1996.
11. Rader DJ, Raper SE, Wilson JM. Gene Therapy for Metabolic Disease. In: *Diabetes Mellitus: A Fundamental and Clinical Text*. LeRoith D, Olefsky J, Taylor S (eds), JB Lippincott Company, Philadelphia; pp. 432-437; 1996.
12. Rader DJ. Disorders of Lipid Metabolism. In: *Textbook of Internal Medicine*. Kelley WN (ed), JB Lippincott Co., Philadelphia; pp. 72-89; 1996.
13. Rader DJ. Approaches to Hypercholesterolemia and Other Abnormal Lipid Profiles. In: *Textbook of Internal Medicine*. Kelley WN (ed), JB Lippincott Co., Philadelphia; pp. 183-191; 1996.
14. Rader DJ. Hark L, Burke F. Nutrition and Pathophysiology: Cardiovascular Disease. In: *Medical Nutrition and Disease*. Morrison G, Hark L (eds), Blackwell Science, Cambridge; pp. 175-203; 1996.
15. Rader DJ, Wilson JM. Gene therapy for familial hypercholesterolemia. In: *Gene Delivery Systems: a state-of-the-art review*. *OECD Documents*, Paris, France 1996; pp. 229-236.
16. Rader DJ. Lipid Disorders. In: *Cardiovascular Medicine*. Topol EJ (ed), Lippincott-Raven, New York, NY; pp. 59-90; 1997.
17. Rader DJ. Atherosclerosis, acute coronary events, and cholesterol-lowering: a new paradigm. *Value in Health* 1:101-104; 1998.
18. Friedrich CA, Rader DJ. Management of Lipid Disorders. *Rheumatic Disease Clinics of North America* 25:1-11; 1999.
19. Tershakovec AM, Rader DJ. Disorders of lipoprotein metabolism and transport. In: *Nelson Textbook of Pediatrics*. 16<sup>th</sup> edition. Behrman RE, Kliegman RM, Jenson HB (eds), WB Saunders, Philadelphia, PA; pp. 387-397; 1999.
20. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader DJ, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole JF, Greengold NL, Rhew DC. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. *JAMA*. 281:1112-20, 1999.
21. Friedrich CA, Rader DJ. Homocysteine and Vascular Disease. *Journal of Clinical Outcomes Management* 6:37-42; 1999.

22. Liang, BT, Rader DJ, Mao, CA. Reducing cardiovascular risk. In *Geriatric Secrets*, 2<sup>nd</sup> Edition. Forciea, MA, Lavizzo-Mourey, R, and Schwab, EP (eds). Hanley & Belfus, Inc., Philadelphia; pp. 70-76; 2000.
23. Mohler ER, Delanty N, Rader DJ, Raps EC. Statins and cerebrovascular disease: plaque attack to prevent brain attack. *Vasc Med* 4:269-272; 2000.
24. Rader DJ, Raper SE, Wilson JM. Gene Therapy for Metabolic Disease. In: *Diabetes Mellitus: A Fundamental and Clinical Text*. 2<sup>nd</sup> Edition. LeRoith D, Olefsky J, Taylor S (eds), JB Lippincott Company, Philadelphia; pp. 526-534; 2000.
25. Rader DJ and Rosas S. Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation. *Med Clin North Am* 84:43-61; 2000.
26. Reilly MP and Rader DJ. Clinical decision-making in the management of lipid disorders. In: *Disease Management & Clinical Outcomes* 3:30-37; 2001
27. Cohen AM and Rader DJ. Dyslipidemia. In: *Current Treatment Options in Cardiovascular Medicine* 3:347-357; 2001
28. Cuchel M, Rader DJ. Cholesterol and all-cause mortality in Honolulu. *The Lancet* 358: 1903-1904: 2001 (letter)
29. Rader DJ. Lipid Disorders. In: *Cardiovascular Medicine*. Topol EJ (2<sup>nd</sup> ed), Lippincott-Raven, New York, NY; pp 43-73: 2002
30. Tershakovec AM, Rader DJ. Disorders of lipoprotein metabolism and transport. In: *Nelson Textbook of Pediatrics*. 17<sup>th</sup> edition. Behrman RE, Kliegman RM, Jenson HB (eds), WB Saunders, Philadelphia, PA; in press
31. Rader DJ, Hobbs HH. Disorders of lipoprotein metabolism. In: *Harrison's Textbook of Medicine*, 16<sup>th</sup> Edition. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds), McGraw-Hill; in press.
32. Dunbar RL, Rader DJ. Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera? *Minerva Endocrinol*. 2004;29(3):89-111. Review.
33. Dunbar RL, Rader DJ. Demystifying triglycerides: a practical approach for the clinician. *Clev Clin J Med*. 2005;72(8):661-6, 670-2, 674-5